Trial Outcomes & Findings for N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use (NCT NCT04627922)

NCT ID: NCT04627922

Last Updated: 2026-08-11

Results Overview

Days of cannabis use will be determined by weekly self-report use of cannabis assessed with Timeline Follow-back (TLFB) which uses a calendar with specific anchor dates to identify the number of 'use days'. The change in the mean number of days reported at baseline and at the week 12 visit will be reported by group.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

41 participants

Primary outcome timeframe

Baseline and 12 weeks

Results posted on

2026-08-11

Participant Flow

59 potential participants signed consent and were assessed for eligibility to participate. 18 of the 59 potential participants were determined to be not eligible to participate and were not enrolled onto the study. A total of 41 eligible participants were enrolled onto the study and randomized to one of the two treatments conditions. This study employed an intent-to-treat model whereby all participants randomized to a treatment condition will be used as the denominator for analyses.

Participant milestones

Participant milestones
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Baseline
STARTED
20
21
Baseline
COMPLETED
20
19
Baseline
NOT COMPLETED
0
2
Week 8
STARTED
20
19
Week 8
COMPLETED
17
16
Week 8
NOT COMPLETED
3
3
Week 12
STARTED
17
16
Week 12
COMPLETED
17
14
Week 12
NOT COMPLETED
0
2

Reasons for withdrawal

Reasons for withdrawal
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Baseline
Withdrawal by Subject
0
2
Week 8
Withdrawal by Subject
3
3
Week 12
Withdrawal by Subject
0
2

Baseline Characteristics

N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 Participants
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 Participants
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Total
n=41 Participants
Total of all reporting groups
Race (NIH/OMB)
White
15 Participants
n=54 Participants
12 Participants
n=54 Participants
27 Participants
n=27 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=54 Participants
6 Participants
n=54 Participants
7 Participants
n=27 Participants
Age, Continuous
56.4 years
STANDARD_DEVIATION 12.3 • n=54 Participants
54.3 years
STANDARD_DEVIATION 12.9 • n=54 Participants
54.8 years
STANDARD_DEVIATION 13.7 • n=27 Participants
Sex: Female, Male
Female
3 Participants
n=54 Participants
3 Participants
n=54 Participants
6 Participants
n=27 Participants
Sex: Female, Male
Male
17 Participants
n=54 Participants
18 Participants
n=54 Participants
35 Participants
n=27 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=54 Participants
0 Participants
n=54 Participants
0 Participants
n=27 Participants
Race (NIH/OMB)
Asian
1 Participants
n=54 Participants
1 Participants
n=54 Participants
2 Participants
n=27 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=54 Participants
1 Participants
n=54 Participants
1 Participants
n=27 Participants
Race (NIH/OMB)
More than one race
2 Participants
n=54 Participants
1 Participants
n=54 Participants
3 Participants
n=27 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=54 Participants
0 Participants
n=54 Participants
1 Participants
n=27 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=54 Participants
1 Participants
n=54 Participants
2 Participants
n=27 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
16 Participants
n=54 Participants
15 Participants
n=54 Participants
31 Participants
n=27 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
3 Participants
n=54 Participants
5 Participants
n=54 Participants
8 Participants
n=27 Participants
Region of Enrollment
United States
20 participants
n=54 Participants
21 participants
n=54 Participants
41 participants
n=27 Participants

PRIMARY outcome

Timeframe: Baseline and 12 weeks

Population: This study employed an intent-to treat model therefore all participants will be included in the analysis for this outcome.

Days of cannabis use will be determined by weekly self-report use of cannabis assessed with Timeline Follow-back (TLFB) which uses a calendar with specific anchor dates to identify the number of 'use days'. The change in the mean number of days reported at baseline and at the week 12 visit will be reported by group.

Outcome measures

Outcome measures
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 Participants
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 Participants
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Change in the Mean Days of Cannabis Use Over Time
-2.20 days of cannabis usage
Standard Deviation 10.91
-0.38 days of cannabis usage
Standard Deviation 11.52

PRIMARY outcome

Timeframe: Baseline and 12 weeks

Population: This study employed an intent-to treat model therefore all participants will be included in the analysis for this outcome.

Weekly self-report use of cigarettes will be assessed with Timeline Follow-back (TLFB) which uses a calendar with specific anchor dates to identify the quantity of use. The change in the mean number of cigarettes used reported at baseline and at the week 12 visit will be reported by group.

Outcome measures

Outcome measures
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 Participants
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 Participants
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Change in the Mean Number of Cigarettes Used Over Time
-83.25 cigarettes
Standard Deviation 235.24
-147.14 cigarettes
Standard Deviation 244.73

PRIMARY outcome

Timeframe: Baseline and 12 weeks

Population: This study employed an intent-to treat model therefore all participants will be included in the analysis for this outcome.

Weekly self-report use of cigarettes will be assessed with Timeline Follow-back (TLFB) which uses a calendar with specific anchor dates to identify the frequency of use. The change in the mean number of days reported at baseline and at the week 12 visit will be reported by group.

Outcome measures

Outcome measures
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 Participants
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 Participants
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Change in the Mean Number of Days of Cigarette Use Over Time
-5.15 days of cigarette useage
Standard Deviation 11.69
-7.00 days of cigarette useage
Standard Deviation 12.50

PRIMARY outcome

Timeframe: At Week 8

Population: This study employed an intent-to treat model therefore all participants will be included in the analysis for this outcome.

Biochemically verified abstinence is defined as a participant self-report of not smoking and a saliva sample to detect the presence or absence of salivary cotinine. Salivary cotinine tests are an established method to biochemically verify a participant's reported smoking status.

Outcome measures

Outcome measures
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 Participants
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 Participants
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Percentage of Participants With Biochemically Verified, Point-prevalent Abstinence at Week 8
10 percentage of participants
0 percentage of participants

PRIMARY outcome

Timeframe: At Week 12

Population: This study employed an intent-to treat model therefore all participants will be included in the analysis for this outcome.

Biochemically verified abstinence is defined as a participant self-report of not smoking and a saliva sample to detect the presence or absence of salivary cotinine. Salivary cotinine tests are an established method to biochemically verify a participant's reported smoking status.

Outcome measures

Outcome measures
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 Participants
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 Participants
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Percentage of Participants With Biochemically Verified Point Prevalent Abstinence at Week 12
10 percentage of participants
4.8 percentage of participants

PRIMARY outcome

Timeframe: Baseline and 12 weeks

Population: This study employed an intent-to treat model therefore all participants will be included in the analysis for this outcome.

The Fagerström Test for Nicotine Dependence is a standard instrument for assessing the intensity of physical addiction to nicotine. It contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. In scoring the Fagerstrom Test for Nicotine Dependence, yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine. The change in the average score by group will be reported.

Outcome measures

Outcome measures
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 Participants
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 Participants
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Change in Scores on the Fagerstrom Test for Nicotine Dependence (FTND) Over Time
-0.45 score on a scale
Standard Deviation 1.43
-0.64 score on a scale
Standard Deviation 1.72

PRIMARY outcome

Timeframe: Baseline and 12 weeks

Population: This study employed an intent-to treat model therefore all participants will be included in the analysis for this outcome.

The QSU-Brief consists of 10 statements about the respondent's feelings and thoughts about his or her desire to smoke cigarettes as he or she is completing the questionnaire (i.e., right now). Each response is scored a number ranging from 1 (strongly disagree) to 7 (strongly agree). The items are summed to yield a total score of 10-70. Higher total scores indicate stronger current smoking urges. The change in the average total score between baseline and week 12 will be reported by group.

Outcome measures

Outcome measures
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 Participants
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 Participants
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Change in Scores on the Questionnaire on Smoking Urges (QSU-Brief): Total Over Time
-4.95 score on a scale
Standard Deviation 14.12
-4.19 score on a scale
Standard Deviation 14.93

PRIMARY outcome

Timeframe: Baseline and 12 weeks

Population: This study employed an intent-to treat model therefore all participants will be included in the analysis for this outcome.

This questionnaire was designed for self-administration and is scored by adding each of the 8 items relating to cannabis use over the past six months. Question 1-7 are scored on a 0-4 scale Question 8 is scored 0,2, or 4. Total score is calculated by summing the items for a total score of 0-32. Total scores of 8 or more indicate hazardous cannabis use, while total scores of 12 or more indicate a possible cannabis use disorder for which further intervention may be required. The change in the average total score between baseline and week 12 will be reported by group.

Outcome measures

Outcome measures
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 Participants
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 Participants
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Change in Scores on the Cannabis Use Disorder Identification Test - Revised (CUDIT-R) Over Time
-3.55 scores on a scale
Standard Deviation 8.02
-3.26 scores on a scale
Standard Deviation 6.90

PRIMARY outcome

Timeframe: Baseline and 12 weeks

Population: This study employed an intent-to treat model therefore all participants will be included in the analysis for this outcome.

This 12-item multidimensional measure assesses cannabis craving based on 4 factors: Compulsivity, Emotionality, Expectancy, Purposefulness. Each item asks about the respondent's feelings and thoughts about smoking marijuana as he or she is completing the questionnaire (i.e., right now). Each response is scored a number ranging from 1 (strongly disagree) to 7 (strongly agree). Each of the 4 factors (subscales) consist of 3 items which are scored by taking the total of the responses in that scale for a total possible subscale score of 3-21. The total score is calculated by summing the total scores for the 4 subscales for a total score range of 12-84 The change in the average total score from baseline to week 12 will be reported by group.

Outcome measures

Outcome measures
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 Participants
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 Participants
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Change in Total Scores on the Marijuana Craving Questionnaire Short Form (MCQ-SF) Total Over Time
-10.40 score on a scale
Standard Deviation 22.24
-4.43 score on a scale
Standard Deviation 21.06

Adverse Events

N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy

Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths

Placebo Comparator: Placebo & Cognitive Behavioral Therapy

Serious events: 0 serious events
Other events: 17 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy
n=20 participants at risk
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Placebo Comparator: Placebo & Cognitive Behavioral Therapy
n=21 participants at risk
Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
Vascular disorders
Flushing
5.0%
1/20 • Up to 12 weeks
28.6%
6/21 • Up to 12 weeks
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, specify
30.0%
6/20 • Up to 12 weeks
52.4%
11/21 • Up to 12 weeks
Skin and subcutaneous tissue disorders
Rash
20.0%
4/20 • Up to 12 weeks
9.5%
2/21 • Up to 12 weeks
Skin and subcutaneous tissue disorders
Urticaria
5.0%
1/20 • Up to 12 weeks
4.8%
1/21 • Up to 12 weeks
Gastrointestinal disorders
Nausea
20.0%
4/20 • Up to 12 weeks
47.6%
10/21 • Up to 12 weeks
Gastrointestinal disorders
Vomitting
10.0%
2/20 • Up to 12 weeks
19.0%
4/21 • Up to 12 weeks
Gastrointestinal disorders
Gastrointestinal disorders - Other, specify
30.0%
6/20 • Up to 12 weeks
38.1%
8/21 • Up to 12 weeks
Gastrointestinal disorders
Diarrhea
30.0%
6/20 • Up to 12 weeks
47.6%
10/21 • Up to 12 weeks
Gastrointestinal disorders
Bloating
5.0%
1/20 • Up to 12 weeks
23.8%
5/21 • Up to 12 weeks

Additional Information

Dr. Ellen Herbst, MD

University of California, San Francisco

Phone: (415) 221-4810

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place